HLB Life Science Co Ltd
067630
Company Profile
Business description
HLB Life Science Co Ltd and its subsidiaries are engaged in the medicare business, bio development business, medical device business, and drug distribution business. The company is a medical device for in vitro diagnostics.The main business is the Medicare business, which includes foot and manufacturing, quasi-drug component development, and finished product consignment production.
Contact
3-10th Floor, Pangyo Seven Venture Valley 1-danji
15, Pangyo-ro 228 beon-gil
Gyeonggi-do
Seongnam-si
KORT: +82 226276700
Sector
Healthcare
Stock type
Defensive
Industry
Medical Distribution
Fiscal Year End
31 December 2026
Employees
187
Stocks News & Analysis
stocks
Hostile takeover on the cards for this ASX income opportunity
IFM lobs reasonable takeover offer.
stocks
Get ready for major US tech earnings starting tomorrow morning
Microsoft, Amazon, Alphabet, and Meta will all release quarterly earnings. Here’s what analysts are looking for.
stocks
Corning’s AI fiber boom is real, but its stock price may be getting out of hand
Corning’s optical fiber business is thriving, and the Meta deal derisks its supply buildout, but success isn’t guaranteed.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,932.10 | 32.40 | 0.36% |
| CAC 40 | 8,104.09 | 37.83 | -0.46% |
| DAX 40 | 24,018.26 | 65.27 | -0.27% |
| Dow JONES (US) | 49,141.93 | 25.86 | -0.05% |
| FTSE 100 | 10,332.79 | 11.70 | 0.11% |
| HKSE | 26,021.95 | 342.17 | 1.33% |
| NASDAQ | 24,663.80 | 223.30 | -0.90% |
| Nikkei 225 | 59,917.46 | 619.90 | -1.02% |
| NZX 50 Index | 12,766.37 | 1.97 | 0.02% |
| S&P 500 | 7,138.80 | 35.11 | -0.49% |
| S&P/ASX 200 | 8,703.90 | 26.30 | 0.30% |
| SSE Composite Index | 4,084.80 | 6.16 | 0.15% |